newsfilter
← Latest News
PR Newswire·

REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2026 Annual Meeting

  • REGENXBIO Inc. announced presentations at the 2026 American Society of Gene & Cell Therapy Annual Meeting (ASGCT 2026) in Boston, Massachusetts, from May 11-15, 2026.
  • Oral presentation 266 titled "Advancing AAV manufacturability toolbox for early programs and beyond" will be delivered by Dr. Metewo Selase Kosi Enuameh on Thursday, May 14, focusing on the NAVXpress manufacturing platform.
  • Oral presentation 506 titled "RGX-202: Investigational gene therapy for Duchenne Muscular Dystrophy" will feature Dr. Aravindhan Veerapandiyan presenting pivotal topline data on Friday, May 15.
  • Poster presentation 1031 by Dr. Brendan Lilley on Tuesday, May 12, highlights NVG82's superior on-target activity compared to AAV8 for outer retinal gene transfer.
  • Poster presentation 3031 by Dr. Huzzatul Mursalin on Thursday, May 14, examines route-dependent ocular transduction of the novel AAV capsid NVG82 in rodent models.
  • Poster presentation 3030 by Dr. Samantha Yost on Thursday, May 14, details an engineered hybrid AAV with reduced liver and DRG transduction & high productivity.
  • Poster presentation 3499 by Dr. Justin Glenn on Thursday, May 14, presents single-nuclei transcriptomic analysis of skeletal muscle mRNA in mdx mice treated with RGX-202.
  • All presentations will be accessible via the Publications page on REGENXBIO's website.
  • REGENXBIO maintains a late-stage pipeline including RGX-202 for Duchenne, RGX-121 & RGX-111 for MPS II & I in partnership with Nippon Shinyaku, & ABBV-RGX-314 for wet AMD & diabetic retinopathy in collaboration with AbbVie.